Relook at lipoprotein (A): Independent risk factor of coronary artery disease in North Indian population
- 21 April 2014
- journal article
- Published by Elsevier BV in Indian Heart Journal
- Vol. 66 (3), 272-279
- https://doi.org/10.1016/j.ihj.2014.03.002
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatmentEuropean Heart Journal, 2013
- Lipoprotein (a) levels in relation to severity of coronary artery disease in north Indian patientsHeart Views, 2013
- Farnesoid X receptor represses hepatic human APOA gene expressionJCI Insight, 2011
- Lipoprotein(a) as a cardiovascular risk factor: current statusEuropean Heart Journal, 2010
- Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular MortalityJAMA, 2009
- Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary eventsNature Reviews Cardiology, 2009
- Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent Advances and Future DirectionsClinical Chemistry, 2003
- Correlation of lipoprotein (a) to angiographically defined coronary artery disease in IndiansInternational Journal of Cardiology, 1996
- Plasma Lp(a) levels correlate with number, severity, and length-extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994
- cDNA sequence of human apolipoprotein(a) is homologous to plasminogenNature, 1987